Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Mismatched unrelated and haploidentical transplant with post-transplant cyclophosphamide-based graft versus host disease prophylaxis are effective for myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJohn E. Levine

Discussion

Loading...

Member takes

Overview

Retrospective analysis found haploidentical transplant and PTCy enhance progression-free survival in myelofibrosis.

Key Points

  • This research investigates the effectiveness of haploidentical and mismatched unrelated transplants in myelofibrosis.
  • Retrospective review of 65 patients undergoing HCT for myelofibrosis from 2015 to 2024.
  • Patients analyzed based on donor type: haploidentical/mismatched versus matched donors.
  • Outcomes evaluated included overall survival, progression-free survival, NRM, and GVHD outcomes.
  • The 2-year overall survival was 73%, while progression-free survival was 66% across the entire cohort.
  • Non-relapse mortality was significantly lower in mismatched recipients at 8% compared to 30% in matched groups.
  • Utilization of post-transplant cyclophosphamide was associated with markedly better GVHD-free relapse-free survival.

Cite This Study

John E. Levine (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d48chttps://doi.org/10.1182/blood-2025-2530
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis using post-transplant cyclophosphamide-based gvhd prophylaxis2025
  2. 2Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study2024 · 17 citations
  3. 3Effect of post-transplant cyclophosphamide on outcomes in stem cell transplant recipients with myelofibrosis2025
  4. 4Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the <scp>EBMT</scp>2025 · 5 citations
  5. 5MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis2025